Pretreatment with a long-acting GnRH agonist for frozen-thawed embryo transfer cycles: how to improve live birth?

Table 3 Multivariable logistic regression analysis on patient’s variable effect on clinical pregnancy and live birth

Covariate	Clinical pregnancy^a		Live birth^b
Covariate	OR (95% CI)	P	OR (95% CI)	P
Age	0.92(0.90–0.94)	0.000	0.91(0.89–0.93)	0.000
PCOS
YES	Reference		1.00
NO	0.69(0.53–0.89)	0.005	0.75(0.58–0.97)	0.032
Endometriosis
YES	1.00		1.00
NO	1.83(1.01–3.33)	0.045	1.53(0.81–2.89)	0.181
Number of transferred embryos	2.09(1.62–2.70)	0.000	1.97(1.50–2.57)	0.000
Grade of transferred embryos		0.000		0.000
Cleavage	0.50(0.39–0.64)		0.53(0.41–0.68)
Blastocyst	1.00		1.00
Endometrial thickness	1.09(1.02–1.16)	0.011	1.07(1.00–1.15)	0.04
Endometrial pattern
Triple line	1.38 (0.95–2.00)	0.082	1.29(0.87–1.9)	0.194
No triple line	1.00		1.00
Form of estrogen administration		0.570		0.548
Without estrogen	1.00		1.00
Estradiol gel	0.67 (0.32–1.38)	0.67	0.73 (0.35–1.52)	0.408
Estradiol valerate	0.66 (0.33–1.35)	0.261	0.75 (0.36–1.54)	0.44
Femoston	0.74 (0.35–1.56)	0.439	0.88 (0.41–1.87)	0.746
Protocol
With GnRha	1.32(1.03–1.70)	0.028	1.34(1.06–1.70)	0.013
Without GnRha	1.00		1.00

OR Odds ratio, CI Confidence interval, PCOS Polycystic ovary syndrome, DOR Decreased ovarian reserve, GnRHa Gonadotropin-releasing hormone agonist, HRT Hormone replacement treatment
^aHosmer–Lemeshow test, p = 0.222
^bHosmer–Lemeshow test, p = 0.343

ISSN: 1757-2215